KOSDAQBiotech & Pharma432980

MFC

₩2,330▲ 2.87%2026-11-18 close
Market Cap
₩20B
Turnover
₩47,176,780
Volume
20K
Shares out.
8.6M
PER
—
PBR
0.7×
EPS
-₩87
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

MFC: Margin Mix Shifts to Statin and Improved-Drug APIs; Profit Durability Is the Test

MFC is shifting its mix toward statin-related and improved-drug APIs, but after a second-quarter 2026 return to operating profit it posted an operating loss in the third quarter, so whether profitability recovery holds is still being tested.

  1. 1

    Revenue rose for a second straight year to KRW 20.8 billion in 2025, but operating profit fell to KRW 297 million, down 79.7% from KRW 1.46 billion in 2024.

  2. 2

    Operating profit returned to KRW 239 million in the second quarter of 2026, then the third quarter swung to an operating loss of KRW 228 million.

  3. 3

    ARIS Independent Research, in a July 2026 report, said the share of statin-related API in sales widened from 31.31% in 2024 to 53.34% in the first quarter of 2026.

  4. 4

    The company said in its August 19, 2026 earnings release that improved-drug APIs Rosuvastatin and Ilaprazole are approaching launch and that large-pharma orders will ship from the fourth quarter.

  5. 5

    In September 2026 the company was named lead institution of a government-funded oral insulin project with a total budget of about KRW 7.1 billion, including KRW 4.8 billion in state support, running through December 2030.

02

Business structure

MFC (Hwaseong-based) was founded in March 2008 as a developer and manufacturer of active pharmaceutical ingredients (APIs), key starting materials (KSMs) and pharmaceutical intermediates (PIs), and listed on KOSDAQ in December 2024 after a merger with a SPAC.

The company has 34 APIs registered with the Ministry of Food and Drug Safety, covering cardiovascular products such as Pitavastatin, Rosuvastatin and Sarpogrelate, digestive-system products such as Trimebutine and Sulglycotide, and anti-inflammatory and analgesic products such as Pelubiprofen and Camostat.

Its core technology is a process that crystallizes TBFA, the KSM for statin-class lipid-lowering drugs, from a liquid into a high-purity solid, and the company says it was the first to commercialize this. Hana Securities also cited this crystallization technology as a basis for differentiated competitiveness.

ARIS Independent Research, in a July 2026 report, analyzed that the share of statin-related APIs in sales widened from 31.31% in 2024 to 53.34% in the first quarter of 2026.

Supply of APIs is the core of the business, and the company describes the market as one where product differentiation in efficacy and function allows share even when alternatives exist.

Customers are domestic and overseas pharmaceutical companies, and joint development with finished-dose makers from the technology stage is expanding. In April 2026 the company said it had completed export talks for Pitavastatin API with a Japanese and a Taiwanese pharmaceutical company.

Its improved-drug API pipeline includes Rosuvastatin, Pitavastatin and Ilaprazole, and new businesses include high-purity ADC linker supply, CDMO cooperation with a domestic partner, and the AI formulation research center launched in January 2026 along with a newly created AI finished-drug division.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.5B₩706,5840.0%
2025Q4₩5B-₩500M−9.1%
2026Q1₩3.2B-₩300M−10.9%
2026Q2₩6B₩200M4.0%
2026Q3₩4.4B-₩200M−5.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩17.3B₩700M-₩700M4.2%−4.1%53.7%
2024₩20.6B₩1.5B-₩1.2B7.1%−4.2%28.5%
2025₩20.8B₩300M₩800M1.4%2.7%18.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Per the DART-filed annual figures, revenue went from KRW 17.3 billion in 2023 to KRW 20.6 billion in 2024 (up 19.0% year on year) and KRW 20.8 billion in 2025 (up 0.9%), rising two years in a row from 2024 to 2025.

Operating profit went from KRW 719 million in 2023 to KRW 1.46 billion in 2024 (up 102.9%) and then fell to KRW 297 million in 2025 (down 79.7%). The operating margin was 4.2% in 2023, 7.1% in 2024 and 1.4% in 2025, with 2024 the highest of the three years.

Hana Securities attributed the 2025 weakness to a temporary drop in orders after drug-price policy changes, and the company said customer orders slowed after the government's drug-pricing reform proposal was announced in November 2025 and demand recovered after the reform was finalized in March 2026.

Net income attributable to controlling shareholders moved from a net loss of KRW 721 million in 2023 and a net loss of KRW 1.18 billion in 2024 (losses continued and widened) to net income of KRW 822 million in 2025, a turn to profit.

Net income including non-controlling interests was reported as a net loss of KRW 721 million in 2023, a net loss of KRW 1.18 billion in 2024 and net income of KRW 822 million in 2025. Operating cash flow was KRW 9.26 million in 2023, KRW 2.65 billion in 2024 and KRW 2.39 billion in 2025.

At the end of 2025, total equity was KRW 30.1 billion, of which KRW 30.1 billion was attributable to controlling shareholders, and total liabilities were KRW 5.62 billion; the debt ratio fell from 53.7% in 2023 to 28.5% in 2024 and 18.7% in 2025.

Quarterly, operating profit was KRW 0.71 million in the third quarter of 2025 on revenue of KRW 4.52 billion; the fourth quarter swung to an operating loss of KRW 454 million on revenue of KRW 5.01 billion (up 10.9% from the prior quarter).

The first quarter of 2026 brought revenue of KRW 3.18 billion (down 36.5% from the prior quarter) and an operating loss of KRW 347 million. The second quarter returned to operating profit of KRW 239 million on revenue of KRW 6 billion (up 88.6% from the prior quarter).

The third quarter of 2026 recorded revenue of KRW 4.39 billion (down 2.7% year on year) and an operating loss of KRW 228 million, a return to losses.

Over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, net losses attributable to controlling shareholders totaled KRW 695 million.

05

Industry analysis

Domestic pharmaceutical makers saw uncertainty rise after the government's drug-pricing reform proposal was announced in November 2025, which slowed customer orders, and demand gradually recovered after the reform was finalized in March 2026.

The company says temporary inventory adjustments across the industry ended and demand returned from the second quarter. The API market is described as one where differences in efficacy and side effects let a product hold share even when substitutes exist.

Product registration and sales used to take a long time, but since 2021 a review system centered on finished drugs has had API makers and finished-dose makers file with regulators together, letting API makers co-develop from an early stage, which MFC is using for improved-drug API development.

In statin-related products, the company is reported to have secured a domestic supply position based on its TBFA crystallization technology, though market-share data is limited. Hana Securities noted the company aims for about 20% share of the key improved-drug API market.

Relative to peers, MFC sits at the API and materials stage rather than the finished-drug stage, so its results depend indirectly on finished-drug approval timing and partner sales.

06

Outlook

In its August 19, 2026 earnings release, the company said it would expand its improved-drug API business in the second half and expects sales of Rosuvastatin and Ilaprazole to contribute to new revenue and profitability.

In a July 2026 report, ARIS Independent Research said Rosuvastatin was scheduled for launch in September 2026 and that 12 customer pharmaceutical companies were preparing product launches.

Hana Securities, in a June 2026 report, said some improved-drug items could launch in the fourth quarter of 2026 if clinical trials succeed. API orders won from large pharmaceutical companies are scheduled to ship from the fourth quarter of 2026.

In September 2026 the company became lead institution of a government-funded oral insulin project with a total budget of about KRW 7.1 billion, including KRW 4.8 billion in state support, running about 54 months through December 2030, with Phase 1 clinical entry and a technology-transfer package targeted by 2030.

Separately, an AI platform for predicting impurities and related substances in drug formulations is being pursued with research funding of about KRW 20 billion over four years and nine months.

The company also secured four patents on crystal-form and formulation technology for a core intermediate of Orforglipron, an oral GLP-1 drug. The company has said it aims to raise operating profit by strengthening product competitiveness.

The next checkpoints are the volume of improved-drug API shipments in the fourth quarter of 2026 and whether the operating margin stays in profit from 2027.

07

Valuation

PER
—
PBR
0.7×
ROE
-2.4%
EPS
-₩87
BPS
₩3,572
Dividend per share
₩0

Over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, net losses attributable to controlling shareholders totaled KRW 695 million, so a price-to-earnings ratio cannot be calculated on earnings.

The price-to-book ratio sits below net asset value, meaning the share price is trading under book equity. At the end of 2025, KRW 30.1 billion of total equity was attributable to controlling shareholders. The dividend yield is below the industry average.

The company decided in June 2026 to buy back KRW 1 billion of its own shares. Reports in June 2026 said CEO Hwang Seong-kwan raised his stake to 33.73% through share purchases.

For valuation, the first checkpoint is whether earnings stabilize in profit, since the third-quarter 2026 operating loss means earnings-based multiples are not yet stable. Over several years, the direction moved from losses in 2023 to profit in 2025, while quarterly results in 2026 alternated between profit and loss.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Higher share of statin-related APIs

ARIS Independent Research analyzed that the share of statin-related APIs in sales widened from 31.31% in 2024 to 53.34% in the first quarter of 2026. The company says it first commercialized high-purity crystallization of TBFA, and Hana Securities cited the technology as a basis for differentiated competitiveness. The API market's structure, in which product differentiation can sustain share, supports this model.

Improved-drug API launches and share target

In August 2026 the company said it is approaching launch of improved-drug APIs including Rosuvastatin and Ilaprazole. ARIS analyzed that Rosuvastatin was scheduled for September 2026 launch with 12 customer companies preparing.

Hana Securities reported that the company aims for about 20% share of key improved-drug API markets. Supporters cite the higher profitability of improved-drug APIs compared with generic APIs.

Government-backed new projects and technology pipeline

In September 2026 the company became lead institution of a government-funded oral insulin project with a total budget of about KRW 7.1 billion, running through December 2030. An AI-based prediction platform is also being pursued with research funding of about KRW 20 billion.

Supply results for high-purity ADC linkers have also been reported. Expansion from API into finished-drug development is cited as a long-term growth axis.

09

Bear factors

Order gap from drug-pricing reform

Hana Securities attributed weakness in 2025 results to a temporary order decline after drug-pricing changes. Revenue rose to KRW 20.8 billion in 2025, but operating profit fell to KRW 297 million. The company said customer orders slowed after the reform was announced in November 2025.

In the first quarter of 2026 revenue fell 36.5% from the prior quarter and an operating loss of KRW 347 million was recorded.

Unstable quarterly profit

Operating profit of KRW 239 million in the second quarter of 2026 turned positive, but the third quarter swung back to an operating loss of KRW 228 million. Over the last four quarters, net losses attributable to controlling shareholders totaled KRW 695 million.

The third-quarter 2026 loss attributable to controlling shareholders was KRW 274 million, with losses widening from a year earlier. Whether profit holds quarter to quarter remains to be seen.

Long development timelines for new businesses

The oral insulin project targets entry into Phase 1 clinical trials by 2030, so commercialization is a long way off. Hana Securities framed some improved-drug API launch timing as contingent on clinical success.

Until new businesses contribute to sales, results will depend more heavily on the statin-related API mix and the drug-pricing environment.

10

Risk factors

Drug-pricing and policy risk

Drug-pricing reform was confirmed to swing quarterly revenue by shifting customer order timing. Orders slowed after the November 2025 proposal and recovered after finalization in March 2026. Similar policy changes could widen quarterly volatility again. The company plans to improve profitability through expanded new-product sales and cost efficiency.

Execution and approval risk for new businesses

The timing of improved-drug API launches depends on customer companies' finished-product approvals and clinical results. The oral insulin project targets Phase 1 entry by 2030, with technical validation and regulatory steps still ahead. The AI platform and CDMO businesses have not yet made a large contribution to reported results.

Ownership concentration and small equity base

According to a June 2026 report, CEO Hwang Seong-kwan's stake was raised to 33.73%. A high concentration of major shareholder holdings can limit free-float supply. Total equity is KRW 30.1 billion, and the small market capitalization may make the share price more volatile.

The company decided in June 2026 to buy back KRW 1 billion of its own shares for share price stability and shareholder value.

11

What to watch next

  1. By end of December 2026

    Whether improved-drug APIs such as Rosuvastatin and Ilaprazole launch and when they show up in sales. A launch would show whether higher-margin items beyond statin products are gaining weight.

  2. During the fourth quarter of 2026

    The shipment volume of API orders won from large pharmaceutical companies. Whether fourth-quarter shipments translate into revenue recovery is the marker for whether the third-quarter operating loss reverses.

  3. By March 31, 2027

    Filing of the 2026 annual business report, which will fix full-year 2026 revenue, operating margin and fourth-quarter results as disclosed figures.

  4. By May 15, 2027

    The deadline for the first-quarter 2027 quarterly report. Whether the statin-related API share holds above half of sales and whether improved-drug API revenue is reflected are the key items to check.

  5. By December 2030

    Target for nonclinical evaluation and Phase 1 entry under the oral insulin project. Progress against this milestone is the benchmark for the feasibility of the new business.

12

Overall view

MFC is shifting its business toward higher-margin APIs, with statin-related products rising from 31.31% of sales in 2024 to 53.34% in the first quarter of 2026.

Revenue rose to KRW 20.8 billion in 2025, a second straight year of growth, but operating profit fell to KRW 297 million, which the company and Hana Securities linked to a temporary order decline after drug-pricing changes.

Operating profit of KRW 239 million in the second quarter of 2026 turned positive, but the third quarter swung back to an operating loss of KRW 228 million, so the profit recovery is still being tested quarter by quarter.

Improved-drug API launches, the fourth-quarter shipment of large-pharma orders, and the oral insulin project with a 2030 target are the business points to watch.

The stock trades below net asset value on a price-to-book basis, but because net losses over the last four quarters totaled KRW 695 million, earnings-based multiples cannot be calculated.

Strengths include the high-purity crystallization technology and the new-business pipeline, while weaknesses include drug-pricing volatility and unstable quarterly profit. The next checkpoint is how full-year 2026 operating margin is fixed in the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. pharm.edaily.co.kr
  2. pharm.edaily.co.kr
  3. news.nate.com
  4. comp.wisereport.co.kr
  5. valueline.co.kr
  6. mfcglobal.co.kr
  7. v.daum.net
  8. investing.com
  9. m.thinkpool.com
  10. mfcglobal.co.kr
  11. vegannews.co.kr
  12. stibee.com
  13. news.nate.com
  14. digitaltoday.co.kr
  15. newspim.com
  16. stibee.com
  17. newspim.com
  18. newspim.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis